News stories about Patheon (NASDAQ:PTI) have been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Patheon earned a news impact score of 0.05 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.5882314411605 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Patheon (NASDAQ PTI) traded up C$0.07 during midday trading on Friday, hitting C$1.63. 73,959 shares of the stock were exchanged, compared to its average volume of 127,861. Patheon has a twelve month low of C$1.53 and a twelve month high of C$16.67.
A number of research analysts have recently commented on PTI shares. Zacks Investment Research raised shares of Patheon from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th. Leerink Swann reissued an “outperform” rating and set a $9.00 target price (down from $17.00) on shares of Patheon in a research report on Wednesday, August 16th.
COPYRIGHT VIOLATION NOTICE: “Patheon (PTI) Getting Somewhat Positive Press Coverage, Analysis Finds” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.dispatchtribunal.com/2017/11/11/patheon-pti-getting-somewhat-positive-press-coverage-analysis-finds.html.
Patheon Company Profile
Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.
Receive News & Ratings for Patheon Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patheon Inc and related companies with MarketBeat.com's FREE daily email newsletter.